ReviewDrugs2016
An Update on Medical Treatment Options for Hidradenitis Suppurativa.
Review in Drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Patient-reported outcomes of laser hair removal for hidradenitis suppurativa: an exploratory cross-sectional survey.Lasers in medical science · 2026Article
- The Multifaceted Role of Keratinocytes in Hidradenitis Suppurativa Pathogenesis.Experimental dermatology · 2026Review
- A Narrative Review of Local Therapies in Hidradenitis Suppurativa: Treatment Landscape and Current Issues.Dermatology and therapy · 2026Review
- Article
- Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.International journal of molecular sciences · 2022Review
- Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology.Antibiotics (Basel, Switzerland) · 2022Article
- Reproductive Potential and Outcomes in Patients with Hidradenitis Suppurativa: Clinical Profile and Therapeutic Implications.Life (Basel, Switzerland) · 2021Article
- Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?American journal of clinical dermatology · 2021Article
- Article
- A Molecular Perspective on the Potential Benefits of Metformin for the Treatment of Inflammatory Skin Disorders.International journal of molecular sciences · 2020Review
- IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa.Clinical and experimental immunology · 2020Review
- Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice.American journal of clinical dermatology · 2020Observational
- Acute form of acne inversa in an 18-week pregnant patient: a case study.Postepy dermatologii i alergologii · 2019Article
- Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms.Therapeutic advances in chronic disease · 2019Review
- The critical role of macrophages in the pathogenesis of hidradenitis suppurativa.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2017Review
- An Atypical Localized Form of Hidradenitis Suppurativa of the Jawline and Neck Mimicking Severe Cystic Acne on Presentation.Skin appendage disorders · 2017Article
- The Clinical Pattern of Axillary Hidradenitis Suppurativa among Saudi Arabians: Mode of Presentation and Treatment Challenges.Journal of cutaneous and aesthetic surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by recurrent inflammatory nodules mostly located in the armpits and groin. Over the years multiple treatments for HS have been proposed; however, to date a cure is still lacking. In this update we provide an overview of most drug treatments reported on for HS, where possible with their mode of action and side effects. In mild cases, clindamycin lotion or resorcinol cream have proven effective. Tetracyclines are a first-line systemic option in more widespread or severe cases, followed by the combination of clindamycin and rifampicin. However, the recurrence rate is high after discontinuation of clindamycin plus rifampicin combination therapy. Long-term treatment with retinoids, especially acitretin is feasible, although teratogenicity has to be taken into account in females of reproductive age. Multiple anti-inflammatory drugs have been suggested for HS, such as dapsone, fumarates or cyclosporine. However, their effectiveness in HS is based on small case series with varying results. If most common treatments have failed, biologics (e.g., infliximab or adalimumab) are the next step. Although not addressed in this review, surgical interventions are often needed to achieve remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.